Chen X-C, Jiao D-C, Qiao J-H, Wang C-Z, Sun X-F, Lu Z-D et al.
Lancet Oncol 2025; 26: 27-36.
Some 689 women were included in the study. The new regimen improved the rate of pathological complete response compared with standard neoadjuvant chemotherapy (66.3 versus 57.6 per cent, P=0.011), without increasing the rate of adverse events.
Comment: Higher complete response rate may improve survival.
.png)
.jpg){kind=logo}
